Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
clinical trials
life sciences
national blog main
5
×
boston blog main
boston top stories
boston
deals
fda
national top stories
new york blog main
san diego blog main
san diego top stories
the medicines company
achaogen
adams street partners
alirocumab
ally bridge group
alnylam pharmaceuticals
amgen
antibiotics
bayer
beta lactamase inhibitor
big data analytics
biomedical advanced research and development authority (barda)
biotech ipos
blackrock
casdin capital
cronos group
diabetic nephropathy
drug resistance
drugs
dyne therapeutics
eventide asset management
evolocumab
focal segmental glomerulosclerosis
ginkgo bioworks
goldfinch bio
hatteras venture partners
hyperammonemia
What
company
5
×
medicines
5
×
drug
bacteria
brings
genetic
ipo
million
new
raised
therapeutics
acquire
agreed
analysis
billion
bio
biology
biopharma
biotech
bioworks
bring
business
called
cash
cholesterol
compound
comprised
deal
develop
developer
developing
disease
diseases
disorders
dyne
dyne’s
employing
engineered
exited
fda
Language
unset
Current search:
company
×
" national blog main "
×
medicines
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections